$145 million pharma acquisition to help launch opioid overdose drug
Indivior’s $145 million acquisition of Opiant Pharmaceuticals will support the launch of OPNT003, an opioid overdose reversal agent.
List view / Grid view
Indivior’s $145 million acquisition of Opiant Pharmaceuticals will support the launch of OPNT003, an opioid overdose reversal agent.
6 May 2015 | By Victoria White
Indivior has announced top-line results from its Phase 3 clinical trial of RBP-7000, an investigational drug for the treatment of schizophrenia...